In vitro studies have shown that IL-10 treatment can convert different types of tumor cells, such as melanoma and lymphoma, to a CTL-resistant phenotype by decreasing the expression of HLA class I molecules on their surface (Petersson et al., 1998; Kurte et al., 2004). The gene discussed is IL10; the disease is melanoma.